- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03502434
Un estudio de prueba de parche de insulto repetido (RIPT) que evalúa el potencial de sensibilización de la solución tópica SM04755 en voluntarios sanos
Un estudio de fase 1, de un solo centro, de prueba de parche de insulto repetido (RIPT) que evalúa el potencial de sensibilización de la solución tópica SM04755
This is a single center, randomized, controlled, within subject comparison, single dose study to determine the sensitization potential of SM04755 solution on normal skin under semi-occlusive patch conditions.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This Phase 1, Repeat Insult Patch Test (RIPT) study is a single-center study of topical SM04755 solution repetitively applied to skin of healthy volunteers. This study will assess the potential of the Test Materials to induce contact sensitization as measured by treatment emergent adverse events (TEAEs), Reaction Grade and Investigator assessment of irritation and sensitization.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Virginia
-
Lynchburg, Virginia, Estados Unidos, 24503
- Research Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Healthy adult males and females at least 18 years of age
- Subjects of any Fitzpatrick skin type or race provided their degree of skin pigmentation does not, in the Investigator or designee's opinion, interfere with study assessments
- Subject has no signs of irritation (i.e., a Reaction Grade of "0") at patch application sites on the back prior to the initial patch application on Day 1
- Subject must have read, understood, and signed the informed consent form prior to any study-related procedure being performed
- Subject is willing and able to comply with all scheduled study visits, urine pregnancy tests (if applicable), contraception requirements (male and female), and other study requirements
- Subject is willing to avoid extensive sun exposure, phototherapy, or use of a tanning salon for the duration of the study
Exclusion Criteria:
- Women who are pregnant or lactating
- Women of childbearing potential who are sexually active and are not willing to use a highly effective method of birth control during the study period that includes double barrier, IUD, or hormonal contraceptive combined with single barrier, or abstinence
- Women of childbearing potential who have had unprotected sexual intercourse within 30 days prior to Day 1
- Males who are sexually active and not willing to use a condom, and have a partner who is capable of becoming pregnant, if neither has had surgery to become sterilized, and/or who are not willing to use double barrier or whose partner is not using a highly effective method of birth control (e.g., IUD, or hormonal contraception combined with single barrier)
- Subject has any skin condition that, in the Investigator's opinion, could interfere with the study assessments or put the subject at undue risk by study participation
- Subject has severe atopic dermatitis/eczema, psoriasis or chronic asthma
- Subject has tattoos, excessive hair, moles, scarring, etc. which would interfere with patching
- Subject has a history of sensitivity to any component of any of the Test Materials
- Use of any of the following medications:
- Systemic or topical glucocorticoids within 4 weeks prior to Day 1
- Systemic or topical analgesics (e.g., NSAIDs, high dose aspirin, etc.) within 1 week prior to Day 1. Note: Daily use of ≤325 mg of aspirin for cardiovascular disease or prophylaxis is allowed. Maximum daily use of Tylenol ≤3000 mg is allowed.
- Antihistamines within 1 week prior to Day 1. Note: H2 blockers such as Pepcid, Zantac, and Tagamet are permitted.
- Anti-inflammatories within 1 week prior to Day 1
- Immunosuppressant medications (e.g., TNF-alpha inhibitors, topical tacrolimus, etc.) within 4 weeks prior to Day 1 (or within 6 half-lives prior to Day 1 for biologics)
- Subject has had previous treatment with SM04755
- Subject has an active infection of hepatitis B or C or human immunodeficiency virus (HIV) infection as determined by an interview
- Participation in a clinical research trial that included the receipt of an investigational product or any experimental therapeutic procedure within 8 weeks prior to Screening, or planned participation in any such trial; the last date of participation in the trial, not the last date of receipt of investigational product, must be at least 8 weeks prior to Screening
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: 90 mg/mL SM04755 in water
90 mg/mL SM04755 in water applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Experimental: 90 mg/mL SM04755 in aqueous Vehicle
90 mg/mL SM04755 in aqueous Vehicle applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Experimental: 90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol)
90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol) applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Otro: Vehicle
Aqueous Vehicle applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Otro: White petrolatum
White petrolatum (Negative control) applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Otro: Sodium lauryl sulfate
Sodium lauryl sulfate (SLS 0.5%) (Positive control) applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Potencial de sensibilización por contacto del material de prueba medido por Tratamiento emergente
Periodo de tiempo: Línea de base hasta el día 40 (o durante el período de observación para los TEAE)
|
Línea de base hasta el día 40 (o durante el período de observación para los TEAE)
|
|
|
Potencial de sensibilización por contacto del material de prueba medido por la evaluación del investigador de irritación y sensibilización
Periodo de tiempo: Línea de base hasta el día 40
|
Línea de base hasta el día 40
|
|
|
Contact sensitization potential of Test Material as measured by Reaction Grade
Periodo de tiempo: Baseline to Day 38-40
|
Reaction Grade is measured on a 5-point scale from zero to four (zero = no sign of irritation and 4 = Erythema with edema and blistering) |
Baseline to Day 38-40
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Yusuf Yazici, M.D., Biosplice Therapeutics, Inc.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades musculoesqueléticas
- Enfermedades Musculares
- Heridas y Lesiones
- Lesiones de tendones
- Tendinopatía
- Compuestos de azufre
- Químicos orgánicos
- Lípidos
- Hidrocarburos
- Alcoholes
- Alcanosulfonatos
- Ácidos alcanosulfónicos
- Ácidos sulfónicos
- Ácidos de azufre
- Alcoholes grasos
- Dodecanol
- Petrolato
- Laurilsulfato Sódico
Otros números de identificación del estudio
- SM04755-TOP-02
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .